Skip to NavigationSkip to content

e-Therapeutics installs new CEO in position

Published on: 11/04/17

e-Therapeutics, a drug discovery company, announced that Dr. Raymond Barlow assumed the position of CEO at the beginning of April. Barlow will enter the position having previously been Executive Director of Corporate Development at Amgen.

Prior to this, he had experience working at Johnson & Johnson as Senior Director of Business Development and began his career with AstraZeneca. He has previously held the role of CEO at Asterion Limited. He will have to bring his varied experience to bear as, at 48 years of age, he is still relatively young to be stepping into the role of CEO.

The new CEO spoke on his appointment:

"e-Therapeutics is at the forefront of a new wave of science and has created a unique, computational-based drug discovery platform. This platform uses a range of truly cutting-edge technologies, including artificial intelligence.

"I am convinced of the value in the platform and our differentiated approach to drug discovery, which should allow us and potential partners to more efficiently discover more effective drug treatments.

"My near-term aim is to ensure that our resources are appropriately focused on activities that are of the greatest commercial potential to support our ambition of creating value for our shareholders. As part of this process, I am looking forward to engaging with our key stakeholders as well as subsequently positioning and promoting the Company to an industry which needs the assets and solutions we can provide."

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches